Bhagavan, Chiranth http://orcid.org/0000-0002-7983-4280
Glue, Paul
Evans, Will
Reynolds, Lisa
Turner, Thivya
King, Chris
Russell, Bruce R.
Morunga, Eva
Mills, Jessica Lee
Layton, Geoff
Menkes, David B.
Funding for this research was provided by:
Saisei Foundation
Article History
Received: 11 December 2023
Accepted: 13 May 2024
First Online: 21 May 2024
Declarations
:
: Approval has been awarded by the Northern B Health and Disability Ethics Committee (NBHDEC) (Ethics Reference: 2022 AM 10467) and the Health Research Council’s Standing Committee on Therapeutic Trials (SCOTT) (Reference: 21/SCOTT106). Medsafe have authorised to distribute 3,4 methylenedioxymethamphetamine (MDMA) and methylphenidate for the purposes of this clinical trial to the following approved investigators: Professor Paul Glue and Dr Will Evans.
: Consent for publication has been obtained from all authors who have reviewed and approved the final manuscript, except for GL who died during the preparation of the manuscript. A copy of the participant information sheet and informed consent form is attached under Additional File 1.
: Professor Paul Glue has a research contract with Douglas Pharmaceuticals to develop novel ketamine formulations for depression.Associate Professor David B. Menkes, Dr Lisa Reynolds and Dr Will Evans have each been employed as an independent contractor for a psychedelic drug trial by New Zealand Clinical Research.All other authors declare that they have no competing interests.